Conference News

Get Ready for CPHI: Off-Patent Semaglutide and Sustainability in a Shifting World

It’s showtime in Frankfurt – with around 62,000 attendees expected.

  • October 27, 2025

  • 5 min

Share

CPHI Frankfurt, set to begin tomorrow, features over 2,400 exhibitors along with keynotes and discussions on sustainability, market dynamics of off-patent semaglutide, and challenges with FDA inspections. The opening ceremony welcomes attendees with breakfast and performances, followed by vital presentations exploring pharmaceutical innovations. The event will additionally reflect on the historic Festhalle venue’s past, from hosting trade fairs to significant wartime events. Jim Macguire emphasizes the need for a deeper understanding of obesity's biological complexities.

Related Content

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.